Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumors

Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumors - Prospective Study of immune-cell therapy for malignant tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004610

Enrollment

600

Registered

2013-04-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patient: 1) Diagnostic imaging or Pathological diagnosis f malignant cancer 2)Performance Status is 0-2 3)No serious abnormality in heart, lung, bone marrow, liver, and renal functions 4) Informed consent has been obtained

Exclusion criteria

Exclusion criteria: Patients who have: 1) T cell, NK cell lymphoma and leukemia 2) HTLV-I Ab and/or HIV Ab positive (LAK therapy), HIV Ab positive (DC therapy) 3) interstitial pneumonia, including their history or predisposition of them, 4) Active autoimmune diseases 5) Active cardiac disease 6) Serious drug allergy 7) Pregnancy woman, or woman with suspected pregnancy, lactating woman 8) Responsible doctors judged the patient inappropriate for the clinical study

Design outcomes

Secondary

Measure	Time frame
Progression free survival Relapse free survival Antitumor effect Quality of life Severe Adverse Event (SAE) Immunological response	—

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactKatsuro Tomita

Kanazawa advanced medical center (KadMedic) Personalized medicine center

meneki@kadmedic.jp076-255-3413

Outcome results